Dodge & Cox Neurocrine Biosciences Inc Transaction History
Dodge & Cox
- $160 Billion
- Q4 2024
A detailed history of Dodge & Cox transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dodge & Cox holds 3,016,425 shares of NBIX stock, worth $347 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
3,016,425
Previous 1,287,820
134.23%
Holding current value
$347 Million
Previous $148 Million
177.7%
% of portfolio
0.26%
Previous 0.09%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.7MCall Options Held
316KPut Options Held
300K-
Black Rock Inc. New York, NY14.2MShares$1.63 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.16 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$563 Million0.03% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$292 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$286 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...